tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Cano Health (CANO), Personalis (PSNL) and Cingulate Inc (CING)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cano Health (CANOResearch Report), Personalis (PSNLResearch Report) and Cingulate Inc (CINGResearch Report).

Cano Health (CANO)

In a report issued on October 20, Jailendra Singh from Truist Financial maintained a Hold rating on Cano Health. The company’s shares closed last Tuesday at $0.12, close to its 52-week low of $0.12.

According to TipRanks.com, Singh has 0 stars on 0-5 stars ranking scale with an average return of -15.8% and a 28.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Privia Health Group, NextGen Healthcare, and Hims & Hers Health.

Cano Health has an analyst consensus of Moderate Sell, with a price target consensus of $0.51.

See the top stocks recommended by analysts >>

Personalis (PSNL)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Personalis today and set a price target of $7.50. The company’s shares closed last Tuesday at $1.07, close to its 52-week low of $0.91.

According to TipRanks.com, Ramakanth has 0 stars on 0-5 stars ranking scale with an average return of -28.5% and a 18.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoPrecise Antibodies, Janux Therapeutics Inc, and ALX Oncology Holdings.

Currently, the analyst consensus on Personalis is a Moderate Buy with an average price target of $5.83.

Cingulate Inc (CING)

H.C. Wainwright analyst Boobalan Pachaiyappan reiterated a Buy rating on Cingulate Inc today and set a price target of $3.50. The company’s shares closed last Tuesday at $0.49, close to its 52-week low of $0.43.

According to TipRanks.com, Pachaiyappan ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -24.4% and a 18.2% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Entrada Therapeutics Inc, Anebulo Pharmaceuticals, and Galera Therapeutics.

Currently, the analyst consensus on Cingulate Inc is a Moderate Buy with an average price target of $5.38.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CANO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles